HCM
VERV

Hollencrest Capital Management’s Verve Therapeutics VERV Stock Holding History

Hollencrest Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-53
Closed -$259 – 1187
2024
Q2 		$259 Hold
53
– – ﹤0.01% 1045
2024
Q1 		$704 Hold
53
– – ﹤0.01% 982
2023
Q4 		$739 Hold
53
– – ﹤0.01% 959
2023
Q3 		$703 Hold
53
– – ﹤0.01% 988
2023
Q2 		$994 Hold
53
– – ﹤0.01% 1024
2023
Q1 		$764 Hold
53
– – ﹤0.01% 1039
2022
Q4 		$1.03K Buy
+53
New +$1.4K ﹤0.01% 1006

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Hollencrest Capital Management's VERV Position: Q3 2024 in Review

Hollencrest Capital Management sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 53 shares — an estimated $259 sold.

Hollencrest Capital Management first reported a position in VERV in Q4 2022 and held it in 7 quarters. The position peaked at $1.03K in Q4 2022. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • Hollencrest Capital Management reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Hollencrest Capital Management sold 53 Verve Therapeutics shares in Q3 2024, an estimated $259.
  • Hollencrest Capital Management first reported a position in Verve Therapeutics in Q4 2022 and held it in 7 quarters.
  • Hollencrest Capital Management's Verve Therapeutics position peaked at $1.03K in Q4 2022.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on Hollencrest Capital Management's 13F filing for Q3 2024, filed 1 Nov 2024.